NASDAQ - ADPT : ADAPTIVE BIOTECHNOLOGIES CO. 11 DEC 2024Buy Call for NASDAQ - ADPT : ADAPTIVE BIOTECHNOLOGIES CO. on 11 DEC 2024.
Buy @ 6.7 with Stop Loss at 6.3.
Take profits at 6.9 and 7.1
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.34 USD
−225.25 M USD
170.28 M USD
142.73 M
About Adaptive Biotechnologies Corporation
Sector
Industry
CEO
Chad Robins
Website
Headquarters
Seattle
Founded
2009
FIGI
BBG001J2PFF5
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
Several Bullish Setups Like This in the MarketFrom small cap to large cap (ex. ROKU), there are several instances like this. The setup is John Carter's 200-500 moving channel. One way to trade this is to sell deep in the money (bull) put spreads. First target on the upside is 13 but timing is tbd. A double daily close below the recent low i
900% profit opportunity within 5 yrsADPT has hust completed wave 2 as a zigzag (wave b being a triangle) and is now primed to start wave 3. Wave 3 is generall 1.618 the lenght of wave 1, putting the next target to 292 dollars. This will take time however and would be a mid-long term investment.
$ADPT missed entry by .10c but still watching . demand zone and profit and stops for me. 3/1 rr with much more if it goes back to ath
ADPT Head and shoulders topBroke strong support and uptrend line with a bearish head and shoulders top pattern.
With the current market situation and possible head and shoulders on IXIC, the incentive to short has increased.
Company losing money, EPS down 97.7% Q/Q, and the measly 98.40M sales do not justify a 7.23B market ca
ADPT H&SLooks to be forming a head and shoulders pattern. On watch for the break higher to upside to around $65. couple days could break down again.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ADPT is 6.39 USD — it has increased by 6.50% in the past 24 hours. Watch Adaptive Biotechnologies Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Adaptive Biotechnologies Corporation stocks are traded under the ticker ADPT.
ADPT stock has risen by 4.58% compared to the previous week, the month change is a 44.57% rise, over the last year Adaptive Biotechnologies Corporation has showed a 29.88% increase.
We've gathered analysts' opinions on Adaptive Biotechnologies Corporation future price: according to them, ADPT price has a max estimate of 10.00 USD and a min estimate of 5.50 USD. Watch ADPT chart and read a more detailed Adaptive Biotechnologies Corporation stock forecast: see what analysts think of Adaptive Biotechnologies Corporation and suggest that you do with its stocks.
ADPT reached its all-time high on Jan 19, 2021 with the price of 71.25 USD, and its all-time low was 2.28 USD and was reached on Apr 19, 2024. View more price dynamics on ADPT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ADPT stock is 11.39% volatile and has beta coefficient of 1.65. Track Adaptive Biotechnologies Corporation stock price on the chart and check out the list of the most volatile stocks — is Adaptive Biotechnologies Corporation there?
Today Adaptive Biotechnologies Corporation has the market capitalization of 943.03 M, it has increased by 2.19% over the last week.
Yes, you can track Adaptive Biotechnologies Corporation financials in yearly and quarterly reports right on TradingView.
Adaptive Biotechnologies Corporation is going to release the next earnings report on Feb 18, 2025. Keep track of upcoming events with our Earnings Calendar.
ADPT earnings for the last quarter are −0.22 USD per share, whereas the estimation was −0.29 USD resulting in a 23.49% surprise. The estimated earnings for the next quarter are −0.26 USD per share. See more details about Adaptive Biotechnologies Corporation earnings.
Adaptive Biotechnologies Corporation revenue for the last quarter amounts to 46.44 M USD, despite the estimated figure of 40.24 M USD. In the next quarter, revenue is expected to reach 46.15 M USD.
ADPT net income for the last quarter is −32.07 M USD, while the quarter before that showed −46.22 M USD of net income which accounts for 30.62% change. Track more Adaptive Biotechnologies Corporation financial stats to get the full picture.
No, ADPT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 709.00 employees. See our rating of the largest employees — is Adaptive Biotechnologies Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Adaptive Biotechnologies Corporation EBITDA is −146.07 M USD, and current EBITDA margin is −105.34%. See more stats in Adaptive Biotechnologies Corporation financial statements.
Like other stocks, ADPT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Adaptive Biotechnologies Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Adaptive Biotechnologies Corporation technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Adaptive Biotechnologies Corporation stock shows the buy signal. See more of Adaptive Biotechnologies Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.